Literature DB >> 17047954

The role of toll-like receptors in systemic lupus erythematosus.

Adeeb H Rahman1, Robert A Eisenberg.   

Abstract

Systemic lupus erythematosus is an autoimmune disease characterized by the production of autoantibodies against a relatively limited range of nuclear antigens. These autoantibodies result in the formation of immune complexes that deposit in tissues and induce inflammation, thereby contributing to disease pathology. Growing evidence suggests that recognition of nucleic acid motifs by Toll-like receptors may play a role in both the activation of antinuclear B cells and in the subsequent disease progression after immune complex formation. The endosomal localization of the nucleic acid-sensing Toll-like receptors (TLRs), TLR3, 7, and 9, is believed to contribute to the distinction between endogenous nucleic acids and those of foreign origin. In this article we review recent work that suggests a role for the B-cell receptor and Fcgamma receptors in delivering nuclear antigens to intracellular compartments allowing TLR activation by endogenous nucleic acids. A number of in vitro studies have presented evidence supporting a role for TLRs in SLE pathology. However, recent studies that have examined the contributions of individual TLRs to SLE by using TLR-deficient mice suggest that the situation is far more complicated in vivo. These studies show that under different circumstances TLR signaling may either exacerbate or protect against SLE-associated pathology. Further understanding of the role of TLRs in pathological autoreactivity of the adaptive immune system will likely lead to important insights into the etiopathogenesis of SLE and potential targets for novel therapies.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17047954     DOI: 10.1007/s00281-006-0034-3

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN: 0344-4325


  99 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

Review 2.  IgG Fc receptors.

Authors:  J V Ravetch; S Bolland
Journal:  Annu Rev Immunol       Date:  2001       Impact factor: 28.527

3.  Human lupus autoantibody-DNA complexes activate DCs through cooperation of CD32 and TLR9.

Authors:  Terry K Means; Eicke Latz; Fumitaka Hayashi; Mandakolathur R Murali; Douglas T Golenbock; Andrew D Luster
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

4.  The immune response modifiers imiquimod and R-848 are potent activators of B lymphocytes.

Authors:  M A Tomai; L M Imbertson; T L Stanczak; L T Tygrett; T J Waldschmidt
Journal:  Cell Immunol       Date:  2000-07-10       Impact factor: 4.868

5.  Cutting edge: cell surface expression and lipopolysaccharide signaling via the toll-like receptor 4-MD-2 complex on mouse peritoneal macrophages.

Authors:  S Akashi; R Shimazu; H Ogata; Y Nagai; K Takeda; M Kimoto; K Miyake
Journal:  J Immunol       Date:  2000-04-01       Impact factor: 5.422

6.  mRNA is an endogenous ligand for Toll-like receptor 3.

Authors:  Katalin Karikó; Houping Ni; John Capodici; Marc Lamphier; Drew Weissman
Journal:  J Biol Chem       Date:  2004-01-16       Impact factor: 5.157

7.  Clinical associations of antiribonucleoprotein antibodies in patients with systemic lupus erythematosus.

Authors:  E J ter Borg; H Groen; G Horst; P C Limburg; A A Wouda; C G Kallenberg
Journal:  Semin Arthritis Rheum       Date:  1990-12       Impact factor: 5.532

Review 8.  Toll-like receptors.

Authors:  Kiyoshi Takeda; Tsuneyasu Kaisho; Shizuo Akira
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

9.  Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation.

Authors:  M Shlomchik; M Mascelli; H Shan; M Z Radic; D Pisetsky; A Marshak-Rothstein; M Weigert
Journal:  J Exp Med       Date:  1990-01-01       Impact factor: 14.307

10.  Delayed apoptotic cell clearance and lupus-like autoimmunity in mice lacking the c-mer membrane tyrosine kinase.

Authors:  Philip L Cohen; Roberto Caricchio; Valsamma Abraham; Todd D Camenisch; J Charles Jennette; Robert A S Roubey; H Shelton Earp; Glenn Matsushima; Elizabeth A Reap
Journal:  J Exp Med       Date:  2002-07-01       Impact factor: 14.307

View more
  34 in total

1.  Requirement of myeloid cell-specific Fas expression for prevention of systemic autoimmunity in mice.

Authors:  Carla M Cuda; Hemant Agrawal; Alexander V Misharin; G Kenneth Haines; Jack Hutcheson; Evan Weber; Joseph A Schoenfeldt; Chandra Mohan; Richard M Pope; Harris Perlman
Journal:  Arthritis Rheum       Date:  2012-03

2.  Fungal pathogen recognition by scavenger receptors in nematodes and mammals.

Authors:  Terry K Means
Journal:  Virulence       Date:  2010 Jan-Feb       Impact factor: 5.882

Review 3.  A model for lupus brain disease.

Authors:  Betty Diamond; Bruce T Volpe
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

Review 4.  MicroRNA, a new paradigm for understanding immunoregulation, inflammation, and autoimmune diseases.

Authors:  Rujuan Dai; S Ansar Ahmed
Journal:  Transl Res       Date:  2011-02-01       Impact factor: 7.012

5.  Btk-specific inhibition blocks pathogenic plasma cell signatures and myeloid cell-associated damage in IFNα-driven lupus nephritis.

Authors:  Arna Katewa; Yugang Wang; Jason A Hackney; Tao Huang; Eric Suto; Nandhini Ramamoorthi; Cary D Austin; Meire Bremer; Jacob Zhi Chen; James J Crawford; Kevin S Currie; Peter Blomgren; Jason DeVoss; Julie A DiPaolo; Jonathan Hau; Adam Johnson; Justin Lesch; Laura E DeForge; Zhonghua Lin; Marya Liimatta; Joseph W Lubach; Sami McVay; Zora Modrusan; Allen Nguyen; Chungkee Poon; Jianyong Wang; Lichuan Liu; Wyne P Lee; Harvey Wong; Wendy B Young; Michael J Townsend; Karin Reif
Journal:  JCI Insight       Date:  2017-04-06

6.  Autoimmunity stimulated by adoptively transferred dendritic cells is initiated by both alphabeta and gammadelta T cells but does not require MyD88 signaling.

Authors:  David A Martin; Kang Zhang; Justin Kenkel; Grant Hughes; Edward Clark; Anne Davidson; Keith B Elkon
Journal:  J Immunol       Date:  2007-11-01       Impact factor: 5.422

7.  Targeting Innate Immunity for CV Benefit.

Authors:  Kathryn J Moore; Mason W Freeman
Journal:  Drug Discov Today Ther Strateg       Date:  2008

8.  Identification of IRAK1 as a risk gene with critical role in the pathogenesis of systemic lupus erythematosus.

Authors:  Chaim O Jacob; Jiankun Zhu; Don L Armstrong; Mei Yan; Jie Han; Xin J Zhou; James A Thomas; Andreas Reiff; Barry L Myones; Joshua O Ojwang; Kenneth M Kaufman; Marisa Klein-Gitelman; Deborah McCurdy; Linda Wagner-Weiner; Earl Silverman; Julie Ziegler; Jennifer A Kelly; Joan T Merrill; John B Harley; Rosalind Ramsey-Goldman; Luis M Vila; Sang-Cheol Bae; Timothy J Vyse; Gary S Gilkeson; Patrick M Gaffney; Kathy L Moser; Carl D Langefeld; Raphael Zidovetzki; Chandra Mohan
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-27       Impact factor: 11.205

9.  Ro60-associated single-stranded RNA links inflammation with fetal cardiac fibrosis via ligation of TLRs: a novel pathway to autoimmune-associated heart block.

Authors:  Robert M Clancy; David Alvarez; Elena Komissarova; Franck J Barrat; Jordan Swartz; Jill P Buyon
Journal:  J Immunol       Date:  2010-01-20       Impact factor: 5.422

10.  Prevention of autoimmune disease by induction of tolerance to Toll-like receptor 7.

Authors:  Tomoko Hayashi; Christine S Gray; Michael Chan; Rommel I Tawatao; Lisa Ronacher; Maureen A McGargill; Sandip K Datta; Dennis A Carson; Maripat Corr
Journal:  Proc Natl Acad Sci U S A       Date:  2009-02-02       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.